Compare Flux Power Holdings Inc (FLUX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Flux Power Holdings Inc trades at $0.43 (market cap $10.06M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 96.7× Flux Power Holdings Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 21 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FLUX | MRVI | |
|---|---|---|
Market Cap | $10.06M | $972.90M |
Volume | 188,430 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $6.66 | $9.00 |
52-Week Low | $0.41 | $2.83 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $18.26M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4652, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported revenue of $66.43 million in 2025 but posted a net loss of $6.67 million, with profitability metrics showing negative ROE and ROA. Recent news highlights acquisition interest from Solidion Technology, which Flux Power's board rejected in October 2026, creating uncertainty around strategic direction.
The outlook remains challenged by persistent losses and declining revenue projections for 2026, though analyst consensus is unanimously bullish with 6 buy ratings. Key risks include execution on profitability, competitive pressures in energy storage, and potential acquisition volatility. The stock's valuation at 0.22 P/S offers potential if operational improvements materialize.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
